Discover 1 curated intelligence briefings related to this specific topic.
The gold rush of GLP-1 agonists has delivered unprecedented weight loss, but at a hidden cost. We investigate the 'Muscle Gap' and the pharmaceutical pivot toward muscle-sparing therapies to prevent a global surge in iatrogenic sarcopenia.
